Skip to main content
https://pbs.twimg.com/media/FrmFOdwXwAIMoQC.png
SURPASS: SEC vs ADA for axSpA Outcome: %pts with no radiographic progression Not benefit- Secukinumab not better than adalimumab Though negative study, in all groups the progression was very low (<1 mSASS) - both interventions did well! @RheumNow #RNL2023 https://t.co/Vt58jSXCMd
Eric Dein
19-03-2023
×